Literature DB >> 7776854

Severe hepatotoxicity related to benzarone: a report of three cases with two fatalities.

M L Hautekeete1, J Henrion, S Naegels, A DeNeve, M Adler, C Deprez, G Devis, G Klöppel.   

Abstract

We report three cases of severe hepatotoxicity related to benzarone, a benzofuran derivative. Our cases include a 35-year-old woman with (sub)fulminant hepatitis, a 67-year-old woman with macronodular cirrhosis, and a 68-year-old man with severe chronic active hepatitis and cirrhosis, with positivity of anti-smooth muscle antibodies. Two patients died. We stress the potential of benzarone to cause hepatotoxicity, which usually resembles severe chronic active hepatitis. Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far, and comprise the first cases of (sub)fulminant hepatitis and cirrhosis related to benzarone.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7776854     DOI: 10.1111/j.1600-0676.1995.tb00102.x

Source DB:  PubMed          Journal:  Liver        ISSN: 0106-9543


  7 in total

Review 1.  Gout in solid organ transplantation: a challenging clinical problem.

Authors:  Lisa Stamp; Martin Searle; John O'Donnell; Peter Chapman
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  Urate-lowering therapy: current options and future prospects for elderly patients with gout.

Authors:  Lisa K Stamp; Peter T Chapman
Journal:  Drugs Aging       Date:  2014-11       Impact factor: 3.923

Review 3.  Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications.

Authors:  Sebastian E Sattui; Angelo L Gaffo
Journal:  Ther Adv Musculoskelet Dis       Date:  2016-05-02       Impact factor: 5.346

4.  [Drug Treatment of Chronic Venous Diesease].

Authors:  Miloš D Pavlović
Journal:  Wien Med Wochenschr       Date:  2016-07-05

5.  The Protein Tyrosine Phosphatase Activity of Eyes Absent Contributes to Tumor Angiogenesis and Tumor Growth.

Authors:  Yuhua Wang; Ram Naresh Pandey; Stephen Riffle; Hemabindu Chintala; Kathryn A Wikenheiser-Brokamp; Rashmi S Hegde
Journal:  Mol Cancer Ther       Date:  2018-05-25       Impact factor: 6.261

6.  Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.

Authors:  F Perez-Ruiz; A Alonso-Ruiz; M Calabozo; A Herrero-Beites; G García-Erauskin; E Ruiz-Lucea
Journal:  Ann Rheum Dis       Date:  1998-09       Impact factor: 19.103

7.  CDER167, a dual inhibitor of URAT1 and GLUT9, is a novel and potent uricosuric candidate for the treatment of hyperuricemia.

Authors:  Ze-An Zhao; Yu Jiang; Yan-Yu Chen; Ting Wu; Qun-Sheng Lan; Yong-Mei Li; Lu Li; Yang Yang; Cui-Ting Lin; Ying Cao; Ping-Zheng Zhou; Jia-Yin Guo; Yuan-Xin Tian; Jian-Xin Pang
Journal:  Acta Pharmacol Sin       Date:  2021-03-25       Impact factor: 6.150

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.